Windlas Biotech Limited

About the company

Incorporated in 2009, Windlas Biotech is one of the top five pharmaceutical formulations manufacturers in India. The company provides a range of CDMO (contract development and manufacturing operations) services such as product discovery, development, licensing and commercial manufacturing of generic products. It offers CDMO services to some of the top names in the pharma industry including Pfizer, Sanofi India and Cadila Healthcare. The company derives around 85% of the revenue from this segment. It also sells its own branded trade generic and OTC products (nutraceutical and health supplement), which contribute around 10% of the total revenue. Besides these segments, the company also garners around 5% of the revenue from exports of generic and health supplements to its primary markets like Vietnam, Myanmar, Sri Lanka, Thailand, Philippines, Cambodia, Fiji, Trinidad & Tobago and South Africa. With the CMDO segment providing stable and steady cash flow, the company has been able to grow its topline consistently. During FY19–21, the company’s revenue has grown at a CAGR of around 18%. But, in the same period, its net profit has shrunk from ₹63.8 crore to ₹15.5 crore.

Financial performance (₹ Cr)

IPO Roadmap / Timeline

1. IPO Opens

   Completed
   04 Aug 2021

   Bidding starts for all investor categories

2. IPO Closes

   Completed
   06 Aug 2021

   Last day to place your bid

3. Basis of Allotment

   Completed
   06 Aug 2021

   Share allotment finalised

4. Refund Initiation

   Completed
   12 Aug 2021

   Refunds credited for non-allottees

5. Credit to Demat

   Completed
   11 Aug 2021

   Allotted shares credited to demat account

6. Listing on Exchange

   Completed
   16 Aug 2021

   Shares list on NSE / BSE

Post-close dates are indicative as per SEBI T+3 listing framework and may change per registrar updates.